NCT05560776Active, not recruiting
Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC
OPTimizing Endobronchial Ultrasound Sampling In Suspected Non Small Cell Lung Cancer for Molecular Markers : A Pragmatic Randomized Controlled TriaL
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. They will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. The co-primary outcomes are 1)the rate of obtention of adequate material for NGS testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 25 Sept 2022
- Start date
- 1 May 2023
- Primary completion date
- 1 May 2026
- Lead sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Diseases
- Lung cancer
- NCT number
- NCT05560776
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 1 May 2023 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Other modality then EBUS judged preferable by treating physician to obtain tumoral tissue for NGS testing
Who the study is looking for
- Suspected or confirmed NSCLC requiring tissue sample for NGS testing to guide clinical management
- Presence of at least 2 targets accessible by EBUS or EUS suspicious of malignancy (primary tumor, lymph node \> 10mm or with Standardized Uptake Value (SUV) \> 2.5)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Universitaire de Cardiologie et Pneumologie de Quebec Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.